The GLP-1 revolution has transformed American and global medicine. Drugs like Ozempic, Mounjaro, Zepbound, and Wegovy have become household names, promising dramatic weight loss and metabolic benefits to millions.
Within the next decade, the global GLP-1 market is projected to exceed $100 billion annually. And no wonder: the sticker price for these drugs in the U.S last year ranged from $1,200 to $1,400 per month, far more than the European average cost of $350.
